Research //

I am actively involved in clinical research and has published extensively. I maintain a strong academic interest and leads on several high profile research projects. I hold an Honorary Associate Professor position at University College London (UCL) and Honorary Senior Lecturer at Queen Mary (QMUL) colleges of the University of London. Click here for my researchgate profile

I am  the Chief Investigator of the PROVENT clinical trial. This trial will evaluate the role of aspirin and vitamin D in preventing progression of indolent prostate cancer, to more sinister disease. The study is well received by men on active surveillance with a high rate of uptake by those who are eligible as it allows those men to feel that they are doing something rather than just waiting and seeing if their cancer will progress. This exemplifies my preference for doing surgery only when it is necessary. The feasibility phase of the study is now complete.

I am  Chief investigator for the NeuroSAFE PROOF study. This is funded through the National Institute for Health Research - Research for Patient Benefit scheme and the JP Moulton Foundation. The study is a randomised controlled study to evaluate a new technique called NeuroSAFE.

Prostate cancer is one of the most common cancers but can often be cured with surgery. Sadly, this sometimes leads to a loss of erections, because the nerves that bring about the erections run in the outer part of the prostate. A process known as nerve sparing, where the outer layers of the prostate are peeled off the prostate, increases the chance of men being potent after surgery. On the other hand, nerve sparing increases the risk of cancer being left behind. Any cancer left behind will need more treatment with radiotherapy that will leave men without the ability to achieve erection, even if they had nerve-sparing surgery.


The prostate is enclosed by a capsule that contains smooth muscle and nerves. Many men having their prostates removed have cancer that extends through the capsule of the prostate. Currently, there isn’t a good way of knowing whether the cancer has spread through the capsule of the prostate and the accuracy of scans like MRI in detecting capsular involvement is limited. Nerve sparing surgery in these patients can cause some cancer to be left behind. A new technique called NeuroSAFE technique may address this problem. It includes a step where a doctor looks at the prostate near where the nerves were, to check for exposed cancer. If cancer is found at the edge of the prostate, the nerve tissue is removed so the chance of the cancer coming back is the same as when cancer cells are not exposed.


We are now actively recruiting to a  large-scale trial where NeuroSAFE will be compared with the current UK practice for prostate cancer (nerve sparing based on an MRI scan, biopsy results and the way the prostate feels).

Provent prostate cancer study logo
dNeuroSAFE Proof prostate cance study logo
Publications //
  1. Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer BJC In Press 2020

  2. NeuroSAFE PROOF Randomised Controlled Feasibility Study:Brief Report of Perioperative outcomes, histological concordance and feasibility. Dinneen, Shaw In Press, Eur Urol 2020

  3. Intraoperative Frozen Section for margin evaluation during Radical Prostatectomy: A Systematic Review. Eoin Dinneen, MIchelle van der Slot, Kelvin Adasonla, Jin Tan, Jack Grierson, Aiman Haider, Alex Freeman, and Eur Urol Focus, In Press 2020

  4. Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, Marzec J, Abdu S, Stankiewicz E, Davies CR, Rajan P, Tipples K, Hines J, Chan PY, Campbell D, Wilkinson K, Kudahetti S, Shamash J, Oliver T, Berney D, Lu YJ. Reply by Authors. J Urol. 2019 Oct 3

  5. Non-invasive detection of clinically significant prostate cancer using circulating tumor cells. J Urol

  6. Use of Magnetic Resonance Imaging (MRI) and biopsy data to guide sampling procedures for prostate cancer biobanking. S Heavey, A Haider, A Sridhar, H Pye, G Shaw, A Freeman, H Whitaker. JOVE video journal, In Press 2019

  7. Thompson JE, …Shaw GL, et al. Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. J Urol. 2019;201(6):1134-43.

  8. Re:”What is the role of NeuroSAFE in robotic radical prostatectomy?” Journal of Robotic surgery. Dinneen E,..Shaw GL In Press 2019

  9. The NeuroSAFE PROOF study protocol. BMJ protocols- In Press 2019

  10. Heavey S PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilising MRI data to target tumour and benign tissue in fresh radical prostatectomy specimens. The Prostate, In Press 2019

  11. C Bailey, RM Bourne, B Siow, EW Johnston, M Appayya.. , A Sridhar, DJ Hawkes, S Punwani, DC Alexander, E Panagiotaki VERDICT MRI validation in fresh and fixed prostate specimens using patient-specific molds for histological and MR alignment. NMR in Biomedicine. In press 2019

  12. Dutto L, Ahmad A, Urbanova K, Wagner C, Schuette A, Addali M, Kelly J.D, Sridhar A, Nathan S, Briggs T.P, Witt J. H, Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts. British Journal of Cancer 2018 119, 1445–1450

  13. A. Warren, C. Massie, .. .. M Asim Feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene.2018 Sep 20 PMID:30237440. Oncogene, 2018

  14. T. Oliver, P.Wilson, W, Ansell, T, Philp, F. Chinegwundoh, J. Shamash, A prospective audit of intermittent anti-androgen verses pituitary blockade suggests a Bipolar Androgen type strategy may be safe in untreated Prostate Cancer. Urol Int. 2017 Dec 22. PMID: 29275414.

  15. AN Sridhar, M Abozaidi, P Rajan, P Sooriakumaran, , S Nathan, JD Kelly, T Briggs Surgical Techniques to Optimize Early Urinary Continence Recovery Post Robot Assisted Radical Prostatectomy for Prostate Cancer. Curr Urol Rep (2017) 18: 71 PMID: 28718165

  16. Learning curves for robotic surgery: a review of the recent literature. Mazzon G, Sridhar A, Busuttil G, Thompson J, Nathan S, Briggs T, Kelly J, , Curr Urol Rep. 2017 Sep 23;18(11):89. Review. PubMed PMID: 28942572.

  17. Asim M. Zecchini HI, Massie CE, Neal DE. Synthetic Lethality between Androgen receptor signaling and PARP pathway in Prostate Cancer. Nat Commun. 2017 Aug 29;8(1):374. PMID: 28851861

  18. Xu L, Mao X, Guo T, Chan PY, Hines J, Stankiewicz E, Wang Y, Oliver T, Ahmad A, Berney D, Shamash J, Lu YJ. The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis Accepted Clinical Cancer Research 2017 Sep 1;23(17):5112-5122. PMID: 28615267.

  19. Bourne RM, Bailey C, Johnston EW, Pye H, Heavey S, Whitaker H, Siow B, Freeman A, , et al. Apparatus for Histological Validation of In Vivo and Ex Vivo Magnetic Resonance Imaging of the Human Prostate. Front Oncol. 2017 Mar 24;7:47. PubMed PMID: 28393049

  20. Tan W, ….., Kelly JD Blood Transfusion Requirement and not Preoperative Anaemia is associated with Perioperative Complications following Intracorporeal Robotic Assisted Radical Cystectomy. J Endourol. 2017 Feb;31(2):141-148. PMID: 27901350.

  21. Johnston T, , Donovan J, Hamdy F, Neal DE, PSA screening improves outcome for men with locally advanced and high risk prostate cancer. Data from the ProtecT trial. European Urology 2017 Mar;71(3):381-388 (In the top 5% of all research outputs scored by Altmetric)

  22. Tan WS, Lamb B, Tan MY, Ahmad I, Sridhar A, Nathan S, Hines J, , Briggs T, Kelly J. An in depth critical analysis of complications following robotic assisted radical cystectomy with intracorporeal urinary diversion. Eur Urol Focus. 2017 Apr;3(2-3):273-279. PMID: 28753745.

  23. Basetti M, , Neal D, Warren A, Griffiths J. Response of Degarelix treatment in human prostate cancer monitored by HR-MAS1H NMR spectroscopy. Metabolomics (2016) 12:120 PMID: 27429605

  24. D Thurtle, , V Gnanapragasam. Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre. BJU Int. 2016 Apr 28.PMID 27124625

  25. Shaw GL, Whitaker H, Corcoran M, Warren A, Neal DE, The rapid effects of castration on human prostate cancer. Eur Urol. 2015 Nov 10 PMID: 26572708

  26. Ross-Adams H, Lamb AD, et al. CamCaP Study Group. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery andvalidation cohort study. EBioMedicine. 2015 Jul 29;2(9):1133-44. PMID: 26501111.

  27. Vasdev N, Agarwal S, Rai BP, Soosainathan A, Chang S, Prasad V, Mohan-S G, Adshead JM. Intraoperative frozen section of the prostate to reduces the risk of positive margin whilst ensuring nerve sparing in patients with Intermediate and high-risk prostate cancer undergoing robotic radical prostatectomy – First Reported UK Series. Curr Urol. 2016 May;9(2):93-103. PMID: 27390582

  28. Asim M, Massie C, Orafidiya F, and Neal DE. Choline kinase alpha is an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst. 2015 Dec 11;108(5). 2016 May. PMID:26657335

  29. Thomas BC, Kay JD, Menon S, Vowler SL, Dawson SN, , Neal DE, Whitaker HC. Whole blood mRNA in prostate cancer reveals a 4-gene androgen regulated panel. Endocrine related cancer 2016 Oct;23(10):797-812. PMID: 27578825.

  30. Pertega-Gomes N, Vizcaino JR , Felisbino S, Warren AY, , Fryer L, Neal DE and Massie CE. MCT2 protein over-expression throughout prostate cancer progression impacts on oncogenic signaling and malignant phenotypes. Oncotarget 2015 Jun 2. PMID:26035357

  31. Shaw GL, Thomas B, Dawson S, Srivastava G, Vowler S, Gnanapragasam V, Shah N, Warren A, Neal D. Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. Br J Cancer. 2014 May 13;110(10):2405-11. PMID: 24722183

  32. Sooriakumaran P, Srivastava A, Shariat SF, , Roobol MJ, Tewari AK Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22,393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. Eur Urol. 2013 Nov 24. PMID: 24290695.

  33. Lewis D, Boren J, , Bielik R, Ramos-Montoya A, Larkin T, Martins C, Neal DE, Soloviev D, Brindle K. Late imaging with [1-11C]acetate PET improves tumour contrast. J Nucl Med. 2014 Apr 28, PMID: 24777291.

  34. A.Ramos-Montoya, A Lamb, R. Russell, V. Theodorou, J. Boren, H.Bon, M.Vias, , N.L Sharma, H.E Scott, SL Vowler, T Carroll, CE Massie, WJ Howat, AY Warren, R. Wooster,I Mills, D.E. Neal. HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med. 2014 May 1;6(5):651-61. PMID: 2473787

  35. Shaw GL. Science made simple- Polymorphism- RFLPs and SNPs, BJU International 09/2013; 112(5).

  36. Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JS, Powles T, Peters JL, Performing cytoreductive nephrectomy following targeted Sunitinib therapy for metastatic renal cell carcinoma- a surgical perspective Urol Int. 2012;89(1):83-8.. PMID: 22614181.

  37. Gnanapragasam V, , Mason M, Neal D, Optimal therapy for high risk localised prostate cancer - should surgery be an option or a preferred primary treatment? BJU Int. 2011 Sep 27. doi: 10.1111/j.1464-410X.2011.10596.x. PMID: 21951841

  38. Boyd L, Xue L, Mao X, Li D, Beltran L, , Hines J, Chaplin T, Berney DM, Bryan D. Young BD, Lu YJ. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multi-focal prostate cancer. Genes Chromosomes Cancer. 2012 Jun;51(6):579-89. PMID: 22334418.

  39. Rouse P, , Ahmed H, Freeman A, Allen C, Emberton M. Multi-parametric Magnetic Resonance Imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urol Int. 2011;87(1):49-53. PMID: 217011

  40. Vasiljević N, Wu K, Brentnall A, Kim DC, Thorat MA., Kudahetti S, Mao X, Xue L, Yu Y, , Beltran L,. Lu YJ, Berney D, Cuzick J and Lorincz AT.Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer using Pyrosequencing. Dis Markers. 2011;30(4):151-61 2011. PMID: 21694441

  41. Shaw GL, Nair R, Peters J. Minerva, BMJ 2010;341:c352

  42. Shaw GL, Ioannou I, Gelister J, Briggs T. Management of Vesico Urethral Anastamosis Disruption after Radical Prostatectomy. Urol Int  84, No. 4,  pp 436-439, 2010, PMID: 20224267

  43. Nair R, Holdroyd D, , Gelister J. Reducing false passages: a novel technique for difficult urethral catheterization. Ann R Coll Surg Engl 2010; 92: 259, PMID: 20425888

  44. Tuffaha H, , Briggs T. Augmented bladder appearance under blue light, J Endourol. Journal of Endourology. June 2010, 24(6): 943-944. PMID: 20367243

  45. Dukic I, , Hussein M, Maraj B. A comparison of handwritten to computerised urological operative notes. Brit J. Med Surg Urol..(2010) 3,22-24

  46. Shaw GL  and Bunce C. Flourescence Cystoscopy- How to do it. Photodiagnosis and Photodynamic Therapy. (2008) 5, 267—270 PMID:19356669

  47. Shaw GL., Emberton M.E, Morgan R,  Berney D., Cuzick J, Oliver R.T.D. Patient designed therapy provides possible “natural” selection evidence for testosterone as differentiating agent for high grade prostate cancer. Brit J. Med Surg Urol. 2009 July 2 (4) 171-173.

  48. Shaw GL and Oliver RTD. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.  J Surg Onc. Mar 2009 PMID:19269165

  49. Ahmed HU, Ishaq A, Zacharakis E, , Illing R, Allen C, Kirkham A,Emberton M. Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy. BJU Int. 2008 Nov 18. 321-3 PMID:19021611

  50. Shaw GL and Prowse DM. Inhibition of androgen independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signaling Cancer Cell Int. 2008 Mar 18;8:3. PMID:18348720

  51. Shaw GL, Ktori E, Price AM, Bisson I,  Purkis P, McFaul S, Oliver RTD and  Prowse DM. Hedgehog Signalling in Androgen Independent Prostate Cancer. European Urology 2008 Dec;54(6):1333-43. PMID:18262716

  52. Mao X, , James SY, Purkis P, Kudahett SK, Tsigan T, Kia1 S, B Young BD, Oliver RTD, Berney D, Prowse DM and Lu YJ. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian Journal of Andrology 2008 May;10(3):467-73. PMID:18385909

  53. Shaw GL and Patel HRH. Transdermal Oxybutynin: a review. Expert Opinion in Pharmacology 2007 Jun;3(3):435-9. PMID: 17539749

  54. Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry N, Oliver RTD. International study into the use of intermittent therapy in the treatment of carcinoma of the prostate (ISICAP), a meta-analysis of 1446 patients. BJUi 2007 May;99(5):1056-65. PMID: 17346277 Cited as a highlight of Urology. Framingham on Urology. Issue 2 2007

  55. Shaw GL, Purkiss T, Oliver RT, Prowse DM. Re: Christine McKillop. Interview with Jack Schalken: PCA3 and its Use as a Diagnostic Test in Prostate Cancer. Eur Urol 2006;50:153-4. PMID:17049717

  56. Shaw GL., Wah TM, Kellett M, Choong S.: Management of renal-vein perforation during a challenging percutaneous nephrolithotomy. J Endourol, 19: 722, 2005 PMID:16053363

  57. Symes A, , Corry, D, Choong S.: Pelvi-calyceal height, a predictor of success when treating lower pole stones with extracorporeal shockwave lithotripsy. Urol Res, 33: 297, 2005 PMID:15937708

  58. Shaw GL, Choong SK, and Fry C.: Encrustation of biomaterials in the urinary tract. Urol Res, 33: 17, 2005  PMID:15614579

  59. Khan MA, , and Paris AM.: Is microscopic haematuria a urological emergency? BJU Int, 90: 355, 2002 PMID 1217538

Book an appointment //

For further advice on urological problems including cancer, please call us on +44 02079359720 to book an appointment, with Mr. Greg Shaw at his private clinic in London. Alternatively, contact us online.

© 2020 Mr Greg Shaw, Consultant Urological Surgeon, London

Book an appointment with Mr Greg Shaw 

Call: 02079359720